Summit Therapeutics PLC Sponsored ADR Stock News

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief E...

Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company...

In a previous clinical trial, Summit's cancer drug ivonescimab showed it was more effective than Keytruda. The excitement propelled Summit's stock to a valuation that at one point reached $27 billion.

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Summit Therapeutics plans to file for a key FDA approval by the end of this year. The drugmaker is betting that the FDA will change its mind on guidance already handed down.

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

SoFi Technologies could become the dominant banking model in the future. Summit Therapeutics is developing a drug with incredible sales potential.